Pfizer’s Dividend Still Pays, But the Cushion Is Narrowing

At roughly $27.55 a share on September 15, Pfizer’s $0.43 quarterly dividend translates into an annualized yield of about 6.2%. That is the kind of number that draws income investors before they examine what sits underneath it. The payout is intact. The coverage is less comfortable.

Pfizer paid $4.9 billion in dividends during the first six months of 2026, while generating $3.45 billion in operating cash flow. That gap does not automatically signal a cut, because pharmaceutical cash receipts and payments can swing sharply between quarters, but it shows why the dividend is no longer supported by the broad cash surplus the company enjoyed during the pandemic. Pfizer’s 2025 operating cash flow was $11.7 billion against $9.8 billion of dividends, leaving a much thinner buffer than the headline yield suggests.

The earnings picture is steadier, at least on Pfizer’s preferred measure. Second-quarter adjusted earnings were $0.77 a share, compared with a $0.43 dividend, and first-half adjusted earnings reached $1.52 a share against $0.86 of dividends. Management reaffirmed full-year adjusted EPS guidance of $2.80 to $3.00, implying a payout ratio near 60% at the midpoint. That is manageable, but the calculation depends on adjusted earnings and assumes Pfizer can keep replacing revenue lost as COVID products fade.

The replacement effort is producing mixed signals. Second-quarter revenue rose 3% to $15.0 billion, with Eliquis, Padcev, Vyndaqel and Lorbrena offsetting steep declines in Paxlovid and Comirnaty. Pfizer said Paxlovid revenue fell 95% operationally from a year earlier, while Comirnaty declined 34%. The company lifted the midpoint of its 2026 revenue outlook to $61.5 billion, but it also reduced its expected COVID-product contribution to roughly $4 billion.

Debt adds another constraint. Pfizer carried about $60.5 billion of long-term debt at June 28, alongside only $976 million of cash, although it also held substantial short-term investments. Interest payments consumed $1.54 billion in the first half. Management says deleveraging remains a priority, yet the capital-allocation framework puts dividends, research spending and future business development ahead of buybacks.

That makes the dividend durable for now, not invulnerable. Investors are being paid to wait for Pfizer’s pipeline and cost cuts to rebuild earnings before the balance sheet forces a harder choice.